Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CLBOE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CM311-18D10-VH6/VL1-ADC
|
|||||
| Synonyms |
CM311-18D10-VH6/VL1-ADC
Click to Show/Hide
|
|||||
| Organization |
SHANGHAI MIRACOGEN INC. | KEYMED BIOSCIENCES CO., LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
CM311-18D10-VH6/VL1
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 64.40% | High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
Patient-derived Xenograft Model were established by tumor tissue with a volume of about 15-30 mm3 was transplanted into the back of BALB/c nude mice subcutaneously, and treatment with 1mg/kg ADCs when the tumor volume reached 150-260 mm3.
|
||||
| In Vivo Model | STO #523 patient-derived xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 0.70% | High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
Patient-derived Xenograft Model were established by tumor tissue with a volume of about 15-30 mm3 was transplanted into the back of BALB/c nude mice subcutaneously, and treatment with 1mg/kg ADCs when the tumor volume reached 150-260 mm3.
|
||||
| In Vivo Model | STO #025 patient-derived xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 93.21% | High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
Patient-derived Xenograft Model were established by tumor tissue with a volume of about 15-30 mm3 was transplanted into the back of BALB/c nude mice subcutaneously, and treatment with 3mg/kg ADCs when the tumor volume reached 150-260 mm3.
|
||||
| In Vivo Model | STO #523 patient-derived xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 100% | High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
Patient-derived Xenograft Model were established by tumor tissue with a volume of about 15-30 mm3 was transplanted into the back of BALB/c nude mice subcutaneously, and treatment with 3mg/kg ADCs when the tumor volume reached 150-260 mm3.
|
||||
| In Vivo Model | STO #025 patient-derived xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 113.8 ng/mL | High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
LI-M11 cells at 5000 cells/well, 1.2mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
|
||||
| In Vitro Model | Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis | LI-M11 cells | CVCL_8891 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 253.9 ng/mL | Moderate Claudin 18.2 expression (Claudin 18.2++) | ||
| Method Description |
LT-1C8 at 5000 or 10000 cells/well, 1.2mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
|
||||
| In Vitro Model | Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis | LT-1C8 cells | CVCL_8891 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 4632 ng/mL | Negative Claudin 18.2 expression (Claudin 18.2-) | ||
| Method Description |
BxPC-3 at 3000 cells/well, 1.2mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 16.37 ng/mL | High Claudin 18.2 expression (Claudin 18.2 +++) | ||
| Method Description |
KATO III cell line was plated at 5000 cells/well, and the samples were added 24 hours later. All samples to be tested were diluted 2.4 folds starting from a final concentration of 1000 ng/mL for 9 times and incubated for 96 hours, and the fluorescence intensity was read by a microplate reader after color development for 60 min with PrestoBlue.
|
||||
| In Vitro Model | Down syndrome | KATO III cells | CVCL_0371 | ||